George F. Tidmarsh
Known title: DirectorCIK: 0001287235
George F. Tidmarsh's purchase track record
How the stock did after each of George F. Tidmarsh's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since February 4, 2022
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-70.3%
3 months: -62.0%
Beat the S&P 500
0%
median -62.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/17/2023 | REVB | $60K | -30.2% | -43.6% | +5.4% |
| 2/25/2022 | REVB | $32K | -62.0% | -70.3% | -7.5% |
| 2/4/2022 | REVB | $207K | -66.3% | -78.9% | -7.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| REVB | ▲ Buy | Grant | 181 | $700 | 2/11/2025 | View on chart |
| REVB | ▼ Sell | Open Market | 27,771 | $14K | 12/8/2023 | View on chart |
| REVB | ▼ Sell | Open Market | 1,845 | $1K | 10/16/2023 | View on chart |
| REVB | ▼ Sell | Open Market | 10,957 | $7K | 10/16/2023 | View on chart |
| REVB | ▼ Sell | Open Market | 1,429 | $986 | 9/28/2023 | View on chart |
| REVB | ▼ Sell | Open Market | 4,000 | $3K | 9/18/2023 | View on chart |
| REVB | ▼ Sell | Open Market | 9,500 | $7K | 9/15/2023 | View on chart |
| REVB | ▼ Sell | Open Market | 12,000 | $9K | 9/14/2023 | View on chart |
| REVB | ▲ Buy | Open Market | 25,000 | $29K | 4/18/2023 | View on chart |
| REVB | ▲ Buy | Open Market | 26,500 | $31K | 4/17/2023 | View on chart |
| REVB | ▲ Buy | Open Market | 20,000 | $32K | 2/25/2022 | View on chart |
| REVB | ▲ Buy | Open Market | 30,000 | $77K | 2/9/2022 | View on chart |
| REVB | ▲ Buy | Open Market | 1,000 | $3K | 2/8/2022 | View on chart |
| REVB | ▲ Buy | Open Market | 42,100 | $110K | 2/7/2022 | View on chart |
| REVB | ▲ Buy | Open Market | 7,900 | $18K | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
REVB announces 1-for-7 reverse stock split effective Oct 20
Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.
REVB announces 1-for-7 reverse stock split effective Oct 20. Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.